Federal Register / Vol. 71, No. 184 / Friday, September 22, 2006 / Notices 55495 

comments will be included in the 

record of the ACOT meeting. 

Dated: September 12, 2006. 

Elizabeth M. Duke, 

Administrator. 

[FR Doc. 06–8024 Filed 9–21–06; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Indian Health Service 

Request for Public Comment: 30-day 

Proposed Information Collection: 

Indian Health Service Contract Health 

Service Report 

AGENCY: Indian Health Service, HHS. 

SUMMARY: The Indian Health Service 

(IHS), as part of its continuing effort to 

reduce paperwork and respondent 

burden, conducts a pre-clearance 

consultation program to provide the 

general public and Federal agencies 

with an opportunity to comment on 

proposed and/or continuing collections 

of information in accordance with the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 3506(c)(2)(A)). This program 

helps to ensure that requested data can 

be provided in the desired format, 

reporting burden (time and financial 

resources) is minimized, collection 

instruments are clearly understood, and 

the impact of collection requirements on 

respondents can be properly assessed. 

As required by section 3507(a)(1)(D) of 

the Act, the proposed information 

collection has been submitted to the 

Office of Management and Budget 

(OMB) for review and approval. 

The IHS received no comments in 

response to the 60-day Federal Register 

notice (71 FR 39686) published on July 

13, 2006. The purpose of this notice is 

to allow an additional 30 days for public 

comment to be submitted directly to 

OMB. 

Proposed Collection: Title: 0917–

0002, ‘‘Indian Health Service Contract 

Health Service Report.’’ Type of 

Information Collection Request: 

Extension of a currently approved 

information collection, 0917–0002, 

‘‘Indian Health Service Contract Health 

Service Report.’’ Form Number: IHS 

843–1A. Need and Use of Information 

Collection: The purpose for the 

collection is to authorize contract health 

care providers to provide health care 

services to eligible IHS patients. The 

IHS form 843–1A ‘‘Order for Health 

Services’’ was developed specifically for 

this collection of information. Other 

than revising the title ‘‘PurchaseDelivery Order for Health Services’’ to 

read ‘‘Order for Health Services’’, 

acquisition terms on the front of the 

form, the contract clauses contained on 

the back of copy 3 of the form, the form 

has not been revised and there is no 

change in the substance or in the use of 

the form. A copy of the form is at 

Attachment 2. 

The majority of the information 

contained in this form is completed by 

IHS staff from existing IHS automated 

patient and vendor data files. Contract 

health care providers complete and sign 

the streamlined form and submit it, 

along with a completed standard 

Centers for Medicare & Medicaid 

Services (CMS) health claim form (CMS 

1450 (UB 92) and CMS 1500), to the IHS 

for verification and payment. The CMS 

forms are used and accepted nationwide by the health care industry and 

IHS is an approved user. 

The information collected is needed 

to administer and manage the contract 

health care services provided to eligible 

American Indian and Alaska Native 

patients. The form is used to: Authorize 

contract health care services for eligible 

patients; certify that the health care 

services requested and authorized have 

been performed by the contract 

provider(s); process payments for health 

care services performed by such 

providers; obtain program data; and, 

serve as a legal document for health and 

medical care authorized by the IHS and 

rendered by health care providers under 

contract with the IHS. 

The information collected is also used 

for: Planning for further care of the 

patient; for keeping an accurate record 

of the patient’s health status and health 

services received and recommended; for 

planning future health care programs; 

for communicating among members of 

the health care team; for evaluating the 

health care rendered; for research and 

continuing education; and, for the 

provision of program health statistics. 

Affected Public: Individuals and 

households. 

Type of Respondents: Individuals. 

The table below provides the 

estimated burden hours for this 

information collection: 

Data collection instrument Est. No. of respondents 

Responses 

per respondent 

Annual number of responses 

Burden per response Total annual 

burden hrs. 

IHS–843–1A ......................................................................... 7,399 42 272,506 0.05 13,625.3 

IDS* ...................................................................................... 13,717 1 13,717 0.05 685.8 

Total .............................................................................. 21,116 ........................ ........................ ........................ 14,311.1 

*Inpatient Discharge Summary (IDS) 

There are no capital costs, operating 

costs and/or maintenance costs to 

respondents. 

Request for Comments: Your written 

comments and/or suggestions are 

invited on one or more of the following 

points: (a) Whether the information 

collection activity is necessary to carry 

out an agency function; (b) whether the 

agency processes the information 

collected in a useful and timely fashion; 

(c) the accuracy of public burden 

estimate (the estimated amount of time 

needed for individual respondents to 

provide the requested information); (d) 

whether the methodology and 

assumptions used to determine the 

estimate are logical; (e) ways to enhance 

the quality, utility, and clarity of the 

information being collected; and (f) 

ways to minimize the public burden 

through the use of automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Direct Comments to OMB: Send your 

written comments and suggestions 

regarding the proposed information 

collection contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, to: Office of Management and 

Budget, Office of Regulatory Affairs, 

New Executive Office Building, Room 

10235, Washington, DC 20503, 

Attention: Allison Eydt, Desk Office for 

IHS. 

FOR FURTHER INFORMATION CONTACT: 

Send requests for more information on 

the proposed collection or to obtain a 

copy of the data collection instrument(s) 

and instructions to Mrs. Christina 

Rouleau, IHS Reports Clearance Officer, 

801 Thompson Avenue, TMP, Suite 450, 

Rockville, MD 20852, call non-toll free 

(301) 443–5938, send via facsimile to 

(301) 443–2316, or send your e-mail 


sroberts on PROD1PC70 with NOTICES
55496 Federal Register / Vol. 71, No. 184 / Friday, September 22, 2006 / Notices 

requests, comments, and return address 

to: crouleau@hqe.ihs.gov. 

Comment Due Date: Your comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

Dated: September 15, 2006. 

Robert G. McSwain, 

Deputy Director, Indian Health Service. 

[FR Doc. 06–8021 Filed 9–21–06; 8:45 am] 

BILLING CODE 4165–16–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

An HIV Protein for Use as a Novel 

Therapeutic or Vaccine Component 

Description of Technology: Latent HIV 

presents a challenge for complete 

removal of the virus in infected 

individuals and is becoming an 

increasingly important consideration in 

the identification of potential HIV 

therapeutics or treatment regimens. 

These transcriptionally inactive HIV 

reservoirs lay dormant in a portion of 

infected cells and are capable of evading 

both host defenses and existing 

antiretroviral therapy. The present 

technology offers a potential solution for 

complete eradication of HIV in infected 

individuals. 

This technology describes 

immunogenic and therapeutic 

compositions related to HIV p28TEV

protein, first protein expressed during 

HIV infection in the case of the pHXB2 

isolate. p28TEV functions in the 

regulation of HIV transcription and may 

be important for the expression of latent 

virus. A number of p28TEV associated 

compositions are available for licensing 

and commercial development including: 

(1) The p28TEV polypeptide from one or 

more HIV clades, (2) nucleic acids 

encoding these p28TEV polypeptides, (3) 

a polypeptide with significant sequence 

homology to p28TEV, and (4) 

immunogenic fragments of these 

polypeptides. Additional compositions 

include antibodies and antagonists that 

act to inhibit p28TEV activity. Adjuvants, 

immunomodulators and compounds 

used in combination with p28TEV for the 

treatment of HIV infection are also 

included in the available technology. 

Applications: (1) Novel therapeutics 

for treatment of HIV infection; (2) Novel 

HIV vaccine component. 

Development Status: Preclinical data 

are available at this time. 

Inventors: Genoveffa Franchini et al. 

(NCI) 

Patent Status: U.S. Patent Application 

No. 11/364,873 filed 27 Feb 2006 (HHS 

Reference No. E–072–2004/3–US–01) 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Susan Ano, PhD; 

301/435–5515; anos@mail.nih.gov. 

Collaborative Research Opportunities: 

The National Cancer Institute Vaccine 

Branch is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Methods of Targeting the 

Establishment of the HIV Viral 

Reservoir. Please contact Betty Tong, 

PhD at 301–594–4263 or 

tongb@mail.nih.gov for more 

information. 

Swine Hepatitis E Virus Available for 

Use in Diagnosis, Prevention and 

Treatment of Hepatitis E 

Description of Technology: Hepatitis E 

virus (HEV) is the cause of Hepatitis E, 

a liver disease that occurs primarily in 

developing countries due to fecal 

contaminated drinking water. Outbreaks 

of HEV infection have caused epidemics 

in Africa, Central and Southeast Asia 

and Mexico and cases of the disease 

have also been reported sporadically in 

more developed countries. Hepatitis E is 

most often overcome by a host’s natural 

defenses; however the disease is more 

severe in pregnant women, who exhibit 

a 20% mortality rate due to HEV 

infection. Presently, no vaccines or 

therapeutic agents, which prevent or 

treat HEV infection, are commercially 

provided. 

An isolated strain of swine HEV is 

currently available for licensing and 

commercial development. The 

nucleotide and amino acid sequences of 

the available virus are significantly 

homologous to human HEV and 

antibodies induced by the agent were 

shown to cross react with a human HEV 

antigen. The present technology 

provides a mechanism for augmenting 

the immune response against HEV in 

infected individuals and is thus useful 

for the development of novel vaccines 

and therapeutics for prevention and 

treatment of HEV infection in humans. 

In addition, the available viral strain 

may be used to develop diagnostic tools 

for efficient detection of HEV 

contamination of food and water in 

developing countries, especially in 

regions of Africa, Asia and Mexico, 

where HEV is endemic. 

Applications: (1) Development of 

diagnostic tools for identification and 

detection of HEV infection; (2) HEV 

vaccination in developing countries, 

where individuals are at higher risk for 

infection; (3) Research and development 

of anti-HEV therapeutics agents. 

Development Status: Preclinical data 

are available at this time. 

Inventors: Xiang-jin Meng, Robert H. 

Purcell, Suzanne U. Emerson (NIAID) 

Patent Status: U.S. Patent No. 

6,432,408 issued 13 Aug 2002 (HHS 

Reference No. E–203–1997/0–US–04) 

and European Patent Application No. 

98934568 filed 17 Jul 1998 (HHS 

Reference No. E–203–1997/0–EP–03) 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Chekesha 

Clingman, PhD; 301/435–5018; 

clingmac@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID Laboratory of Infectious 

Diseases, Hepatitis Viruses Section, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

swine HEV or its products. Please 

contact Robert H. Purcell at 

rpurcell@niaid.nih.gov for more 

information. 

Dated: September 18, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–8080 Filed 9–21–06; 8:45 am] 

BILLING CODE 4140–01–P 


sroberts on PROD1PC70 with NOTICES